Objective We assessed trends and risk factors for trichomoniasis since the publication of the 2014 BASHH trichomoniasis management guideline and following the addition, in 2021, of recommended [demographically and geographically] targeted screening for this infection. Methods We described gender-stratified trends in trichomoniasis diagnoses at sexual health services in England from 2012-2023 using data from the GUMCAD STI surveillance system. We determined gender-stratified factors associated with trichomoniasis diagnosis. Results Nationally, trichomoniasis diagnoses increased by 38% between 2012 and 2019 (6,950 to 9,490 diagnoses); after a drop in 2020 due to COVID-19, diagnoses increased by 54% between 2021 and 2023 (5,907 to 9,102 diagnoses). For women, trichomoniasis infection was associated with older age groups (aged 45+, aOR: 2.75 [95% CI:2.53-2.98] vs 15-25yrs). Women self-reporting Black Caribbean ethnicity (aOR: 3.21 [95% CI: 2.95-3.50]) and any other black background (aOR: 3.75 [95% CI:3.25-4.34]) had higher odds of trichomoniasis diagnosis than people of White British ethnicity. Trichomoniasis diagnoses were associated with living in the most deprived areas (vs. least deprived; aOR 3.25 [95% CI: 2.91-3.63]), living in the West Midlands (vs. London; aOR 2.12, [95% CI: 1.96-2.28]) and in Yorkshire and Humber (vs. London; aOR 1.44, [95% CI: 1.31-1.58]). Similar factors were observed to be associated with a diagnosis of trichomoniasis amongst men. Discussion The targeted screening of women either at high risk of infection (and their partners) or living in areas of higher prevalence, and the introduction of NAAT testing has likely contributed to the increase in diagnoses, especially among Black ethnicities. Although diagnoses have increased in all areas and ethnic groups, the increased likelihood of trichomoniasis among some racially minoritised groups shows the potential effect of compounding sources of health inequity, something which highlights the need for targeted, culturally competent interventions to address this.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All data were collected within statutory approvals granted to the UK Health Security Agency for infectious disease surveillance and control. The UK Health Security Agency has approval to handle data obtained by the GUMCAD STI surveillance system under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002. Information was held securely and in accordance with the Data Protection Act 2018 and Caldicott guidelines.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

In its role providing infectious disease surveillance, UK Health Security Agency has permission to handle data obtained through the GUMCAD STI Surveillance System under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002. Requests for aggregate data can be made by contacting the GUMCAD (GUMCADukhsa.gov.uk), where all publicly released data must adhere to UKHSA data sharing guidelines.